Ovchinnikov, Arkady Matveevich (2024). Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: real-world experience of two Swiss Multiple Sclerosis centers. (Thesis). Universität Bern, Bern
|
Text
24ovchinnikov_am.pdf - Thesis Available under License Creative Commons: Attribution (CC-BY 4.0). Download (478kB) | Preview |
Abstract
Background Ocrelizumab (OCR) is a humanized monoclonal antibody directed against CD-20 positive lymphocytes, mainly B-lymphocytes. OCR is approved for treatment of primary progressive (PPMS) and relapsing multiple sclerosis (RMS). This study aims to provide real-world safety and efficacy data of people with RMS treated with OCR in two Swiss Multiple Sclerosis (MS) centers. Methods We have conducted a retrospective data analysis using the patient cohorts from the Cantonal Hospital Aarau and Bern University Hospital (RMS: n = 235). Statistical analyses were performed with Mann–Whitney U-Test, Chi-squared test and Spearman-Rho-Correlation. Adjustment for multiple testing was performed by Bonferroni procedure. Results After initiation of OCR, there was a decrease in disease activity in RMS patients. In our study, 152/190 (80.0 %) RMS patients fulfilled the criteria for NEDA-3 12 months and 88/104 (84.6 %) showed NEDA-3 24 months after OCR initiation. The most frequent adverse events (AEs) in our study were infections, taking place in 78/235 (33.2 %) RMS patients. COVID-19 was the most common infection, followed by urinary infections and other respiratory infections and infectious adverse events occurred significantly more frequent in patients with reduced IgG serum concentration. Conclusions Our real-world study showed OCR being associated with low rates of any type of MS disease activity as indicated by NEDA-3. The adverse event profile is comparable to the known events especially infections and an association between infections and reduced IgG serum concentration was found.
| Item Type: | Thesis |
|---|---|
| Dissertation Type: | Single |
| Date of Defense: | 24 April 2024 |
| Subjects: | 600 Technology > 610 Medicine & health |
| Institute / Center: | 04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
| Depositing User: | Hammer Igor |
| Date Deposited: | 21 May 2024 16:35 |
| Last Modified: | 21 May 2024 21:21 |
| URI: | https://boristheses.unibe.ch/id/eprint/5071 |
Actions (login required)
 |
View Item |